Abstract
Nerve cells communicate via the release of chemical messengers (neurotransmitters) which bind to a site (receptor) on another or the same cell causing an effect. The various neuroreceptor classes are responsible for important functions such as movement, memory, and learning. Naturally occurring neurotransmitters are agonists, molecules that trigger an effect in the target cell after binding to the receptor site. In most cases, the binding period of an agonist to the receptor is short and after release from the receptor, the agonist is rapidly taken up by the same nerve cell (reuptake) or metabolized by various bioenzymes. Antagonists are artificial “false” neurotransmitters that bind to a receptor, often with similar or higher affinity compared to an agonist, but do not cause an effect in the target receptor other than preventing the binding of the agonist. Typically, antagonists are designed to increase the binding affinity to the receptor site, to delay release from the receptor pocket, and inhibit the metabolism by bioenzymes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
REFERENCES
Burgen, A. S. V. (1995) The background of the muscarinic system. Life Sci. 11/ 12: 801–806.
Mutschler, E., Moser, U., Wess, J., and Lambrecht, G. (1989) Muscarinic receptor subtypes: agonists and antagonists, in Progress in Pharmacology and Clinical Pharmacology, vol. 7/1, (Zwieten, P. A. and vanand-Schonbaum, E., eds.), Gustav Fischer Verlag, Stuttgart, pp. 13–31.
Buckley, N. J., Bonner, T. I., Buckley, C. M., and Brann, M. R. (1989) Antagonist binding properties of five cloned muscarinic receptors expresses in CHOK1 cells. Mol. Pharmacol. 35, 469–476.
Gainetdinov, P. R. and Caron, M. G. (1999) Delineating muscarinic receptor functions. Proc. Natl. Acad. Sci. USA 96, 12,222–12,223.
Levey, A. I. (1993) Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 52, 441–448.
Levey, A. I. (1996) Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc. Natl. Acad. Sci. USA 93, 13,541–13,546.
Brown, J. H. and Taylor, P. (1996) Muscarinic receptor agonists and antagonists, in The Pharmacological Basis of Therapeutics (Hardman, J. G. and Limbird, L. E., eds.), McGraw-Hill, NY, pp 141–160.
Baghdoyan, H. A. and Lydic, R. (1999) M2 muscarinic receptor subtype in the feline medial pontine reticular formation modulates the amount of rapid eye movement sleep. Sleep 22, 835–847.
Nordberg, A., Alaguzoff, I., and Winblad, B. (1992) Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J. Neurosci. Res. 31, 103–111.
Freund, G. and Ballinger, W. E. (1991) Loss of synaptic receptors can precede morphologic changes induced by alcoholism. Alcohol Alcoholism (Suppl. 1), 385–391.
Kinney, H. C., Filiano, J. J., Sleeper, L. A., Mandel, L. F., Valdes-Dapena, M., and White, W. F. (1995) Decreased muscarinic receptor binding in the arcuate nucleus in sudden infant death syndrome. Science 269, 1446–1450.
Nagren, K., Halldin, C., Muller, L., Swahn, C. G., and Lehikoinen, P. (1995) Comparison of [11C]methyl triflate and [11C]methyl iodide in the synthesis of PET radioligands such as [11C]beta-CIT and [11C]beta-CFT. Nucl. Med. Biol. 22, 965–979.
Prenant, C., Barre, L., and Crouzel, C. (1989) Synthesis of [11C]-3-quinuclidinyl benzilate (QNB). J. Labelled Comp. Rad. 27, 1257–1265.
Halldin, C., Farde, L., Hogberg, T., Hall, H., Strom, P., Ohlberger, A., and Solin, O. (1991) A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamindes. Preparation and in vitro dopamine D-2 receptor binding. Nucl. Med. Biol. 18, 871–881.
Lang, L., Jagoda, E., Schmall, B., Vuong, B. K., Adams, R., Nelson, D. L., Carson, R. E., and Eckelman, W. C. (1999) Development of fluorine-18-labeled 5HT1A antagonists. J. Med. Chem. 42, 1576–1586.
Seevers, R. H. and Counsell, R. E. (1982) Radioiodination techniques for small organic molecules. Chem. Rev. 82, 575–590.
Kampfer, I., Heinicke, J., Sorger, D., Schulze, K., Schliebs, R., and Knapp, W. H. (1996) Novel preparation of (R,R)bromo-3-quinuclidinyl benzilate (Br-QNB), a precursor for the synthesis of (R,R)[123I]iodo-QNB. J. Labelled Comp. Rad. 38, 1047–1052.
Sternbach, L. H. and Kaiser, S. (1952) Antispasmodics. I. Bicyclic basic alcohols. J. Am. Chem. Soc. 74, 2215–2218.
Beckett, A. H., Lan, N. T., and Khokhar, A. Q. (1971) Anti-acetylcholinesterase activity of some stereoisomeric aminoboranes. J. Pharm. Pharmacol. 23, 528–533.
Rzeszotarski, W. J., Eckelman, W. C., Francis, B. E., Simms, D. A., Gibson, R. E., Jagoda, E. M., et al. (1984) Synthesis and evaluation of radioiodinated derivatives of 1-azabicyclo[2.2.2]oct-3-yl α-hydroxy-α-(4-iodophenyl)-α-phenylacetate as potential radiopharmaceuticals. J. Med. Chem. 27, 156–159.
Kiesewetter, D. O., Silverton, J. V., and Eckelman, W. C. (1995) Synthesis and biological properties of chiral fluoroalkyl quinuclidinyl benzilates. J. Med. Chem. 38, 1711–1719.
Gibson, R.E. (1990) Muscarinic acetylcholine receptors, in Quantitative Imaging. Neuroreceptors, Neurotransmitters, and Enzymes (Frost, J. J., Wagner, H. N., Jr., eds.), Raven Press, Boston, MA, pp. 129–152.
Eckelman, W. C., Reba, R. C., Rzeszotarski, W. J., Gibson, R. E., Hill, T., Holman, B.L., et al. (1984) External imaging of cerebral muscarinic acetylcholine receptors. Science 223, 291–294.
Holman, B. L., Gibson, R. E., Hill, T. C., Eckelman, W. C., Albert, M., and Reba, R. C. (1985) Muscarinic acetylcholine receptors in Alzheimer’s disease, in vivo imaging with iodine 123-labeled 3-quinuclidinyl 4-iodobenzilate and emission tomography. JAMA 254, 3063–3066.
Weinburger, D. R., Gibson, R., Coppola, R., Jones, D. W., Molchan, S., Sunderland, T., et al. (1991) The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. A controlled study with 123IQNB and single photon emission computed tomography. Arch. Neurol. 48, 169–176.
Owens, J., Murray, T., McCulloch, J., and Wyper, W. (1992) Synthesis of (R,R)-[123I]-QNB, a SPECT imaging agent for cerebral muscarinic acetylcholine receptors in vivo. J. Labelled Comp. Rad. 31, 45–60.
Weinburger, D. R., Jones, D., Reba, R. C., Mann, U., Coppola, R., Gibson, R., et al. (1992) A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementias. J. Neuropsychiatry Clin. Neursci. 4, 239–248.
Wyper, J., Brown, D., Patterson, J., Owens, J., Hunter, R., Teasdale, E., and McCulloch, J. (1993) Deficits in iodine-labelled 3-quinuclidinyl benzilate binding in relation to cerebral blood flow in patients with Alzheimer’s disease. Eur. J. Nucl. Med. 20, 379–386.
Sunderland, T., Esposito, G., Molchan, S. E., Coppola, R., Jones, D. W., Gorey, J., et al. (1995) Differential cholinergic regulation in Alzheimer’s patients compared to controls following chronic blockade with scopolamine: a SPECT study. Psychopharmacology 121, 231–241.
Laduron, P. M. and Janssen, P. F. M. (1979) Characterization and subcellular localization of brain muscarinic receptors labelled in vivo by [3H]dexetimide. J. Neurochem. 33, 1223–1231.
Wilson, A. A., Dannals, R. F., Ravert, H. T., Frost, J. J., and Wagner, H. N., Jr. (1989) Synthesis and biological evaluation of [125I]-and [123I]-4-iododexetimde, a potent muscarinic cholinergic receptor antagonist. J. Med. Chem. 32, 1057–1062.
Boundy, K. L., Barnden, L. R., Rowe, C. C., Reid, M., Kassiou, M., Katsifis, A. G., and Lambrecht, R. M. (1995) Human dosimetry and biodistribution of iodine-123-iododexetimide: a SPECT imaging agent for cholinergic muscarinic neuroreceptors. J. Nucl. Med. 36, 1332–1338.
Muller-Gartner, H. W., Wilson, A. A., Dannals, R. F., Wagner, H. N., Jr., and Frost, J. J. (1992) Imaging muscarinic cholinergic receptors in human brain in vivo with SPECT, [I-123]-4-iododexetimide and [I-123]-4-iodolevetimide. J. Cereb. Blood Flow Metab. 12, 562–570.
Muller-Gartner, H. W., Mayberg, H. S., Fisher, R. S., Lesser, R. P., Wilson, A. A., Ravert, H. T., et al. (1993) Decreased hippocampal muscarinic cholinergic receptor-binding measured by I-123 iododexetimide and single photon emission computed tomography in epilepsy. Ann. Neurol. 34, 235–238.
Boundy, K. L., Rowe, C. C., Black, A. B., Kitchener, M. I., Barnden, L. R., Sebben, R., et al. (1996) Localization of temporal lobe epileptic foci with iodine-123 iododexetimide cholinergic neuroreceptor single-photon emission computed tomography. Neurology 47, 1015–1020.
Weckesser, M., Hufnagel, A., Ziemons, K., Griessmeier, M., Sonnenberg, F., Hacklander, T., et al. (1997) Effect of partial volume correction on muscarinic cholinergic receptor imaging with single-photon emission tomography in patients with temporal lobe epilepsy. Eur. J. Nucl. Med. 24, 1156–1161.
Claus, J. J., Dubois, E. A., Booij, J., Habraken, J., de Munck, J. C., van Herk, M., et al. (1997) Demonstration of a reduction in muscarinic receptor binding in early Alzheimer’s disease using iodine-123 dexetimide single-photon emission tomography. Eur. J. Nucl. Med. 24, 602–608.
McPherson, D. W., DeHaven-Hudkins, D. L., Callahan, A. P., and Knapp, F. F., Jr. (1993) Synthesis and biodistribution of iodine-125-labeled 1-azabicyclo[2.2.2]oct-3-yl α-hydroxy-α-(1-iodo-1-propen-3-yl)-α-phenylacetate. A new ligand for the potential imaging of muscarinic receptors by SPECT. J. Med. Chem. 36, 848–854.
McPherson, D. W., Lambert, C. R., Jahn, K., Sood, V., McRee, R. C., Zeeberg, B., et al. (1995) Resolution, in vitro and in vivo evaluation of isomers of iodine-125-labeled 1-azabicyclo[2.2.2]oct-3-yl α-hydroxy-α-(1-iodo-1-propen-3-yl)-α-phenylacetate (IQNP). A high affinity ligand for the muscarinic receptor. J. Med. Chem. 38, 3908–3917.
Rayeq, M. R., Boulay, S. F., Sood, V. K., McPherson, D. W., Knapp, F. F., Jr., Zeeberg, B. R., and Reba, R. C. (1996) In vivo autoradiographic evaluation of isomers of I-125-labeled 1-azabicyclo[2.2.2.]oct-3-yl α-hydroxy-α-(1-iodo-1-propen-3-yl)-α-phenylacetate (IQNP). Direct evidence for enhanced in vivo M2 muscarinic subtype selectivity for Z-(-) (-)-[125I]-IQNP. Receptors Signal Transduction 6, 13–34.
McPherson, D. W., Greenbaum, M., Luo, H., Beets, A. L., and Knapp, F. F., Jr. (2000) Evaluation of Z-(R,R)-IQNP for the potential imaging of the m2 mAChR rich regions of the brain and heart. Life Sci. 66, 885–896.
Bergstrom, K. A., Halldin, C., Hiltunen, J., Swahn, C. G., Ito, H., Ginovert, N., et al. (1998) I-125 and I-123-labeled E-(-,-)-IQNP: potential radioligand for visualization of M1 acetylcholinergic receptors in brain. Determination of metabolites using HPLC. Nucl. Med. Biol. 25, 209–214.
Bergstrom, K., Halldin, C., Savonen, A., Okubo, Y., Hiltunen, J., Nobuhara, K., et al. (1999) Iodine-123 labelled Z-(R,R)-IQNP: A potential radioligand for visualization of M1 and M2 muscarinic acetylcholine receptors in Alzheimer’s disease. Eur. J. Nucl. Med. 26, 1482–485.
Nobuhara, K., Halldin, C., Hall, H., Karlsson, P., Farde, L., Hiltunen, J., et al. (2000) Z-IQNP: A potential radioligand for SPECT imaging of muscarinic acetylcholine receptors in Alzheimer’s disease. Pyschopharmacology (Berl.) 149(1), 45–55.
Nobuhara, K., Farde, L., Halldin, C., Karlsson, P., Swahn, C. G., Olsson, H., et al. (2000) SPECT imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP. Eur. J. Nucl. Med, in press.
Vora, M. M., Finn, R. D., Boothe, T. E., Liskwosky, D. R., and Potter, L. T. (1983) [N-Methyl-11C]scopolamine: synthesis and distribution in rat brain. J. Labelled Comp. Rad. 20, 1229–1236.
Frey, K. A., Koeppe, R. A., Mulholland, G. K., Jewett, D., Hichwa, R., Ehrenkaufer, R. L. E., et al. (1992) In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography. J. Cereb. Blood Flow Metab. 12, 147–154.
Varastet, M., Brouillet, E., Chavoix, C., Prenant, C., Crouzel, C., Stulzaft, O., et al. (1992) In vivo visualization of cerebral muscarinic receptors using [11C]quinuclidinyl benzilate and positron emission tomography in baboons. Eur. J. Pharmacol. 213, 275–284.
Dannals, R. F., Langstrom, B., Ravert, H. T., Wilson, A. A., and Wagner, H. N., Jr. (1988) Synthesis of radiotracers for studying muscarinic cholinergic receptors in the living human brain using positron emission tomography: [11C]dexetimide and [11C]levetimide. Appl. Radiat. Isot. 39, 291–295.
Dewey, S. L., MacGregor, R. R., Brodie, J. D., Bendriem, B., King, P. T., Volkow, N. D., et al. (1990) Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine. Synapse 5, 213–223.
Dewey, S. L., Volkow, N. D., Logan, J., MacGregor, R. R., Fowler, J. S., Schlyer, D. J., and Bendriem, B. (1990) Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET). J. Neurosci. Res. 27, 569–579.
Ono, S., Kawashima, R., Ito, H., Koyama, M., Goto, R., Inoue, K., et al. (1996) Regional distribution of the muscarinic cholinergic receptor in the human brain studies with 11C-benztropine and PET using an anatomical standardization technique. Kaku Igaku 33, 721–727.
Mulholland, G. K., Otto, C. A., Jewett, D. M., Kilbourn, M. R., Koeppe, R. A., Sherman, P. S., et al. (1992) Synthesis, rodent biodistribution, dosimetry, metabolism, and monkey images of carbon-11-labeled (+)-2α tropanyl benzilate: A central muscarinic receptor imaging agent. J. Nucl. Med. 33, 423–430.
Koeppe, R. A., Frey, K. A., Mulholland, G. K., Kilbourn, M. R., Buck, A., Lee, K. S., and Kuhl, D. E. (1994) [11C]Tropanyl benzilate-binding to muscarinic cholinergic receptors: methodology and kinetic modeling alternatives. J. Cereb. Blood Flow Metab. 14, 85–99.
Lee, K. S., Frey, K. A., Koeppe, R. A., Buck, A., Mulholland, G. K., and Kuhl, D. E. (1996) In vivo quantification of cerebral muscarinic receptors in normal human aging using positron emission tomography and [11C]tropanyl benzilate. J. Cereb. Blood Flow Metab. 16, 303–310.
Mulholland, G. K., Kilbourn, M. R., Sherman, P., Carey, J. E., Frey, K. A., Koeppe, R. A., and Kuhl, D. E. (1995) Synthesis, in vivo biodistribution and dosimetry of [11C]N-methylpiperidinyl benzilate ([11C]NMPB), a muscarinic acetylcholine receptor antagonist. Nucl. Med. Biol. 22, 13–17.
Zubieta, J. K., Koeppe, R. A., Mulholland, G. K., Kuhl, D. E., and Frey, K. A. (1998) Quantification of muscarinic cholinergic receptors with [11C]NMPB and positron emission tomography: method development and differentiation of tracer delivery from receptor binding. J. Cereb. Blood Flow Metab. 18, 619–631.
Suhara, T., Inoue, O., Kobayashi, K., Suzuki, K., and Tateno, Y. (1993) Agerelated changes in human muscarinic acetylcholine receptors measured by positron emission tomography. Neurosci. Lett. 149, 225–228.
Suhara, T., Inoue, O., Kobayashi, K., Satoh, T., and Tateno, Y. (1994) An acute effect of triazolam on muscarinic cholinergic receptor binding in the human brain measured by positron emission tomography. Psychopharmacology (Berl.) 113, 311–317.
Shinotoh, H., Asahina, M., Inoue, O., Suhara, T., Hirayama, K., and Tateno, Y. (1994) Effects of trihexyphenidyl and L-dopa on brain muscarinic cholinergic receptor binding measured by positron emission tomography. J. Neural. Transm. [P-D Sect] 7, 35–46.
Asahina, M. and Shinotoh, H. (1997) Muscarinic cholinergic receptor imaging of parkinsonian brains using 11C-NMPB and PET. Nippon Rinsho. 55, 233–237.
Yoshida, T., uwabara, Y., Ichiya, Y., Sasaki, M., Fukumura, T., Ichimiya, A., et al. (1998) Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer’s disease patients on 11C-N-methyl-4-piperidinyl benzilate. Comparison with cerebral blood flow and cerebral glucose metabolism. Ann. Nucl. Med. 12, 35–42.
Sudo, Y., Suhara, T., Honda, Y., Nakajima, T., Okubo, Y., Suzuki, K., et al. (1998) Muscarinic cholinergic receptors in human narcolepsy: a PET study. Neurology 51, 1297–1302.
Takahashi, K., Murakami, S., Miura, S., Iida, H., Kanno, I., and Uemura, K. (1999) Synthesis and autoradiographic localization of muscarinic cholinergic antagonist (+)-N-methyl-3-piperidinyl benzilate as a potent radioligand for positron emission tomography. Appl. Rad. Isot. 50, 521–525.
Wilson, A. A., Scheffel, U. A., Dannals, R. F., Stathis, M., Ravert, H. T., and Wagner, H. W., Jr. (1991) In vivo biodistribution of two [18F]-labelled muscarinic cholinergic receptor ligands: 2-[18F]-and 4-[18F]fluorodexetimide. Life Sci. 48, 1385–1394.
Luo, H., Beets, A. L., McAllister, M. J., Greenbaum, M., McPherson, D. W., and Knapp, F. F., Jr. (1998) Resolution, in vitro and in vivo evaluation of fluorine-18-labeled isomers of 1-azabicyclo[2.2.2]oct-3-yl α-fluoroalkyl-α-hydroxy-α-phenylacetate (FQNPe) as new PET candidates for the imaging of muscarinic-cholinergic receptor. J. Labelled Comp. Rad. 41, 681–704.
Takahashi, K., Miura, S., Hatazawa, J., Shimosegawa, E., Kinoshita, T., Ito, H., et al. (1999) Synthesis of [18F]fluoroethyl-4-piperidinyl benzilate, a muscarinic receptor antagonist, for use in receptor activation studies with PET. J. Labelled Comp. Rad. 42, S497–S499.
Doods, H., Entzeroth, M., Ziegler, H., Schiavi G., Engel, W., Mihm, G., et al. (1993) Characterization of BIBN 99: a lipophilic and selective muscarinic M2 receptor antagonist. Eur. J. Pharmacol. 242, 23–30.
Aubert, C., Perrio-Huard, C., and Lasne, M. C. (1997) Synthesis of [11C]BIBN 99, a new selective radioligand for the in vivo studies of M2 muscarinic receptors by PET. J. Labelled Comp. Rad. 40, 752–754.
Aubert, C., Perrio-Huard, C., and Lasne, M. C. (1997) Synthesis of [11C]BIBN 99, a new selective radioligand for the in vivo studies of M2 muscarinic receptors by PET. J. Labelled Comp. Rad. 40, 752–754.
McPherson, D. W., Breeden, W., Luo, H., Beets, A., and Knapp, F. F., (1998) Resolution, radiolabeling and in vivo evaluation of the isomers of IPIP. An attractive ligand for imaging mAChR. J. Nucl. Med. 39, 49.
McPherson, D., Halldin, C., Hall, H., Nobuhara, K., Sandell, J., Knapp, F.F., Jr., and Farde, L. (1999) Evaluation of carbon-11 labeled E-(R)-IPIP for the potential PET imaging of muscarinic receptors. J. Labelled Comp. Rad. 42, S378–S380.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc. Totowa, NJ
About this protocol
Cite this protocol
W. McPherson, D. (2001). Targeting Cerebral Muscarinic Acetylcholine Receptors with Radioligands for Diagnostic Nuclear Medicine Studies. In: Lopatin, A.N., Nichols, C.G. (eds) Ion Channel Localization. Methods in Pharmacology and Toxicology. Humana Press. https://doi.org/10.1385/1-59259-118-3:17
Download citation
DOI: https://doi.org/10.1385/1-59259-118-3:17
Publisher Name: Humana Press
Print ISBN: 978-0-89603-833-2
Online ISBN: 978-1-59259-118-3
eBook Packages: Springer Protocols